Associated Events

Breakfast with Andy Walshe: Hacking Human Potential

Breakfast with Andy Walshe: The ECU Exercise Medicine Research Institute and AICC(WA) Annual Event 2016.  Hacking Human Potential. Presented by Andy Walshe, Director of High Performance, Red Bull. 

Registrations are now open! 

Start: May 6, 2016 7:00 am
End: May 6, 2016 9:00 am
Location: Banquet Hall
Price: $52.00

Click here to book.

Workshop: Australian Genomics Health Alliance (AGHA) - Update and Roundtable Discussion

Date: Wednesday 4th May 2016
Time: 5pm to 7pm
Venue: Room 12- Perth Convention and Exhibition Centre     
Cost: Free                                                                                                   

Brief Overview of workshop
Professor Kathryn North, the Director of Murdoch Children’s Research Institute who is leading the Australian Genomics Health Alliance (AGHA) together with Professor Andrew Sinclair, will give an update on AGHA and have a roundtable discussion with Members of the Alliance.

2-hour meeting (including light refreshments and snacks)

Invitation only event
This meeting is invitation only, for members of the Australian Genomics Health Alliance (AGHA). All WA members and associates will be invited personally, but interstate members of AGHA who are attending Science on the Swan are also welcome to attend. However, please can they RSVP to Tina Ly on by April 25th 2016 so that we can cater appropriately.

Includes early evening canapés and drinks (Tea/Coffee/Hot Chocolate)

Contact to attend:      
Name: Tina Ly - EA to Professor Nigel Laing
T: 0411 838 143

Telethon Kids Research Seminars

Lions Eye Institute Seminar Series

Dr Lyndon daCruz Will be presenting a talk entitled Stem Cell Rescue of Retinal Disease

Sponsored by the Miocevich Family

Wednesday 4th May
Harry Perkins Institute of Medical research
Seminar room G24, ground floor
Light refreshments: 5.30pm
Presentation: 6.00pm – 7.00pm

RSVP  to Jade Knapp for catering purposes.

Lyndon da Cruz was born in Mombasa, Kenya and, as a child moved to Perth, Western Australia.  In 1982 a degree in Philosophy and Physiology took him to Oxford University in 1990 and following the degree he remained in the UK to complete the fellowship of the Royal College of Ophthalmologists based at the Oxford Eye Hospital. In 1995 he returned to Western Australia on an NHMRC (National Health and Medical Research Council) Scholarship where he was awarded a PhD from UWA for his research on Gene Transfer to the Retinal Pigment Epithelium in 1999.

In 2000 he was awarded the Howard Florey Fellowship from the Royal Society, London that brought him to Moorfields Eye Hospital and the Institute of Ophthalmology. A post – doctoral fellowship at the Institute of Ophthalmology in Retinal Gene therapy and a medical retinal fellowship with Professor Alan Bird followed. In 2003 he was appointed Consultant Ophthalmic Surgeon in medical and surgical retina at Moorfields Eye Hospital and Honorary Reader at the Institute of Ophthalmology, University College London. In 2015 he was awarded a full professorship in Retinal Stem Cell and Transplantation Surgery at UCL. Professor da Cruz is chief investigator and surgeon for the bionic eye implantation project in London. His interest also includes working with stem cell therapy, translocation surgery for people with age-related macular degeneration (AMD). He is currently clinical lead on The London Project for transplanting stem-cell-derived retinal cells for patients with Macular Degeneration.

Summary of the Lecture Dr Lyndon daCruz will be presenting:

Stem Cells Rescue of Retinal Disease

The identification of stable stem cell sources and the advances in stem cell technology have transformed this area of research science into an important area of strong therapeutic possibility. These sources include human embryonic stem cells (HESC), induced pleuripotent stem cell sources (iPS) as well as adult sources. The main advantage of using a stem cell source is that there is an infinite capacity to reproduce and therefore an infinite capacity to produce cells for transplantation.  The challenge more recently has been to transform these stem cells into differentiated cells that are useful for transplantation in disease.  In terms of the retina HESC have been successfully developed into retinal pigment epithelial cells.  These cells have been characterised as identical to native human RPE cells structurally functionally and biochemically. Previous studies of macular translocation and RPE/choroidal transplantation have shown that vision loss from AMD can be reversed.  Early animal studies show that the transplanted HESC RPE survive and can prevent vision loss in animal models of disease.  We have carried out the first 2 transplantations in the London Project’s RPE transplantation trial with promising results. I will also briefly discuss the recent advances in neuro-retinal reconstruction using stem cells, which will be necessary if this area of research medicine is to genuinely contribute to the treatment of retinal disease.